iifl-logo

Granules India Ltd Share Price

491.2
(1.67%)
Apr 3, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open492
  • Day's High502.5
  • 52 Wk High721
  • Prev. Close483.15
  • Day's Low485.55
  • 52 Wk Low 389.35
  • Turnover (lac)7,177.04
  • P/E36.31
  • Face Value1
  • Book Value137.58
  • EPS13.3
  • Mkt. Cap (Cr.)11,911.29
  • Div. Yield0.31
View All Historical Data
Loading...
  • Roll Over%0
  • Roll Cost0
View More Futures

Granules India Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

492

Prev. Close

483.15

Turnover(Lac.)

7,177.04

Day's High

502.5

Day's Low

485.55

52 Week's High

721

52 Week's Low

389.35

Book Value

137.58

Face Value

1

Mkt Cap (₹ Cr.)

11,911.29

P/E

36.31

EPS

13.3

Divi. Yield

0.31

Granules India Ltd Corporate Action

15 May 2024

12:00 AM

BookCloser

arrow

15 May 2024

12:00 AM

AGM

Announcement Date: 15 May, 2024

arrow

25 Mar 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

15 May 2024

12:00 AM

Dividend

Dividend Amount: 1.5

Record Date: 30 Jul, 2024

arrow

Granules India Ltd NEWS AND UPDATE

LIC Increases Stake in Granules India to 5.02%
4 Mar 2025|09:37 PM

The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.

Read More
Granules India’s Gagillapur Facility Receives USFDA Warning Letter
27 Feb 2025|11:16 PM

Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.

Read More
Granules India Secures USFDA Approval for Andhra Facility
12 Nov 2024|10:14 AM

The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.

Read More
Granules India Secures USFDA Nod for Bupropion SR Tablets
20 Oct 2024|07:33 PM

Bupropion hydrochloride is widely prescribed for treating major depressive disorder (MDD) and preventing seasonal affective disorder (SAD).

Read More
Granules India’s Gagilapur unit gets 6 observations from USFDA
12 Sep 2024|03:26 PM

The USFDA has also noted a repeat observation from the company's January 2023 inspection.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Granules India Ltd SHAREHOLDING SNAPSHOT

03 Apr, 2025|06:50 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.35%

Foreign: 0.35%

Indian: 38.49%

Non-Promoter- 35.43%

Institutions: 35.43%

Non-Institutions: 25.71%

Custodian: 0.00%

Share Price

Granules India Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

24.24

24.2

24.8

24.77

Preference Capital

0

0

0

0

Reserves

3,086.71

2,675.26

2,505.86

2,137.85

Net Worth

3,110.95

2,699.46

2,530.66

2,162.62

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

3,238.43

3,134.98

2,309.92

1,646.64

yoy growth (%)

3.29

35.71

40.28

22.02

Raw materials

-1,757.74

-1,509.64

-1,221.98

-903.09

As % of sales

54.27

48.15

52.9

54.84

Employee costs

-282.79

-318.25

-192.51

-147.92

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

519.64

732.87

391.9

208.45

Depreciation

-126.16

-118.45

-101.82

-75.91

Tax paid

-133.13

-180.08

-108.95

-69.29

Working capital

350.84

159.58

230.57

276.19

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

3.29

35.71

40.28

22.02

Op profit growth

-25.16

74.31

68.34

-0.76

EBIT growth

-29.16

80.68

73.48

1

Net profit growth

-30.07

24.48

219.1

-2.56

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

4,490.16

4,511.92

3,764.92

3,237.54

2,598.65

Excise Duty

0

0

0

0

0

Net Sales

4,490.16

4,511.92

3,764.92

3,237.54

2,598.65

Other Operating Income

16.21

0

0

0

0

Other Income

4.4

13.78

17.61

26.88

89.79

Granules India Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,713.65

130.564,11,3061,181.050.795,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,666

72.521,50,342.825940.532,297513.62

Cipla Ltd

CIPLA

1,452.35

25.211,17,322.541,438.150.894,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,207.1

59.541,08,614.114850.872,330222.38

Mankind Pharma Ltd

MANKIND

2,421.9

51.6699,891.45416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Granules India Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

C Krishna Prasad

Executive Director

Harsha Chigurupati

Executive Director

Uma Devi Chigurupati

Non-Exec & Non-Independent Dir

K B Sankara Rao

Company Sec. & Compli. Officer

Chaitanya Tummala

Non-Exec. & Independent Dir.

Arun Sawhney

Independent Director

Saumen Chakraborty

Independent Director

Sucharita Rao Palepu

Joint Managing Director & CEO

KVS Ram Rao

Independent Director

Kapil Mehan

Independent Director

Rajiv Kakodkar

Executive Director

Priyanka

Independent Director

S Ravi

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Granules India Limited is a large-scale vertically integrated company founded in March 18th, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD). With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin. The company has a global presence across over 80 countries servicing over 300 customers. Granules India is the preferred supplier for some of the worlds leading pharma branded and generics companies. The company has one of largest PFI and single site FD facilities in the world. It is also home to one of the Worlds largest Paracetamol API facilities.Granules India has 8 manufacturing facilities, out of which six are located in India and two in the US. It also has two operational manufacturing units located in India and China through its joint venture entities. The company has 250 customers present across 60 countries around the globe. The companys research center at Pragathi Nagar, Hyderabad, spread across an area of 15,000 square feet, epitomizes the companys focus on research and development. It mainly focuses on full-scale generic API development.Incorporated as a private limited company in 1991, Granules India (GIL) was converted into a public limited company in Feb.93. It commenced its operations i
Read More

Company FAQs

What is the Granules India Ltd share price today?

The Granules India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹491.2 today.

What is the Market Cap of Granules India Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Granules India Ltd is ₹11911.29 Cr. as of 03 Apr ‘25

What is the PE and PB ratio of Granules India Ltd?

The PE and PB ratios of Granules India Ltd is 36.31 and 3.65 as of 03 Apr ‘25

What is the 52 Week High and Low of Granules India Ltd?

The 52-week high/low is the highest and lowest price at which a Granules India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Granules India Ltd is ₹389.35 and ₹721 as of 03 Apr ‘25

What is the CAGR of Granules India Ltd?

Granules India Ltd's CAGR for 5 Years at 27.95%, 3 Years at 15.41%, 1 Year at 8.43%, 6 Month at -18.86%, 3 Month at -20.61% and 1 Month at 2.18%.

What is the shareholding pattern of Granules India Ltd?

The shareholding pattern of Granules India Ltd is as follows:
Promoters - 38.85 %
Institutions - 35.44 %
Public - 25.71 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.